A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of …
M Ranson, H Shaw, J Wolf, M Hamilton… - Cancer chemotherapy …, 2010 - Springer
Purpose An intravenous (IV) erlotinib formulation has not been characterized in cancer
patients but may be useful in those with gastrointestinal abnormalities that impact on the …
patients but may be useful in those with gastrointestinal abnormalities that impact on the …
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with …
N Yamamoto, A Horiike, Y Fujisaka… - Cancer chemotherapy …, 2008 - Springer
Purpose The objectives of this phase I dose-finding study of erlotinib were to investigate the
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …
toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess …
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in oncology, 2003 - Elsevier
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
A Patnaik, D Wood, AW Tolcher, M Hamilton… - Clinical cancer …, 2006 - AACR
Purpose: To assess the feasibility of administering erlotinib, an inhibitor of epidermal growth
factor receptor (EGFR) tyrosine kinase, in combination with paclitaxel and carboplatin, and …
factor receptor (EGFR) tyrosine kinase, in combination with paclitaxel and carboplatin, and …
Preclinical studies with erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - Elsevier
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature
Erlotinib is currently marketed at fixed standard dosage against pancreatic cancer and non–
small-cell lung carcinoma. However, erlotinib pharmacokinetics (PK) is characterized by …
small-cell lung carcinoma. However, erlotinib pharmacokinetics (PK) is characterized by …
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer
JF Lu, SM Eppler, J Wolf, M Hamilton… - Clinical …, 2006 - Wiley Online Library
Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient
population with solid tumors, identify covariates, and explore relationships between …
population with solid tumors, identify covariates, and explore relationships between …
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors
AR Hanauske, J Cassidy, J Sastre, C Bolling… - Clinical cancer …, 2007 - AACR
Abstract Purpose: Erlotinib (Tarceva) is a potent epidermal growth factor receptor (HER1)
inhibitor. Infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) is a standard …
inhibitor. Infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) is a standard …
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101
AA Miller, DJ Murry, K Owzar, DR Hollis… - Journal of clinical …, 2007 - ascopubs.org
Purpose We investigated dose and pharmacokinetics of erlotinib in patients with hepatic
dysfunction or renal dysfunction. Patients and Methods Patients were assigned to one of …
dysfunction or renal dysfunction. Patients and Methods Patients were assigned to one of …
Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine
H Kletzl, M Giraudon, PS Ducray, M Abt… - Anti-cancer …, 2015 - journals.lww.com
The aim of this study was to evaluate the effect of coadministration of acid-reducing agents
on the pharmacokinetic exposure of orally administered epidermal growth factor receptor …
on the pharmacokinetic exposure of orally administered epidermal growth factor receptor …
相关搜索
- erlotinib in patients solid tumors
- dose escalation epithelial origin
- dose finding solid tumors
- erlotinib in patients safety relationship
- erlotinib in patients clinical pharmacokinetics
- safety relationship solid tumors
- japanese patients dose finding
- clinical pharmacokinetics solid tumors
- erlotinib tarceva clinical potential
- erlotinib tarceva pharmacokinetics and pharmacodynamics
- japanese patients solid tumors